非酒精性脂肪肝治疗进展  

Advances in the Treatment for Nonalcoholic Fatty Liver Disease

作　　者：黄婷婷[1,2] 周玉荣[1,2] 张向君[1] 刘沙沙[1,2] 殷晶晶 王加林 

机构地区：[1]蚌埠医学院研究生部,安徽蚌埠233000 [2]解放军第八二医院内分泌科,江苏淮安223001

出　　处：《医学综述》2015年第8期1406-1409,共4页Medical Recapitulate

摘　　要：非酒精性脂肪肝(NAFLD)是西方国家最常见肝病,在我国的发病率日益上升,且呈低龄化趋势。胰岛素抵抗在NAFLD的发生发展中起关键作用。目前暂无批准治疗NAFLD的药物,但许多治疗方法是有益的。生活方式改变仍是治疗NAFLD的基础。体质量减轻可改善肝脂肪变性,且体质量减轻10%甚至可以改善脂肪肝炎。此外,常用的胰岛素增敏剂、抗氧化剂和调脂抗炎药物同样是治疗NAFLD比较有前景的药物。肠促胰岛素疗法有可能改善肥胖和糖尿病的肝脂肪变性。由此研发的新型糖尿病治疗药物胰高血糖素样肽1类似物相对于NAFLD传统治疗手段表现出了更广阔的潜在价值。同时,减重手术的不断发展,对治疗NAFLD合并病态肥胖患者具有独特的临床意义。Nonalcoholic fatty liver disease（NAFLD） is the most common liver disease in western world. Its incidence is increasing rapidly in China and is showing a trend in younger ages .Insulin resistance is believed to play a crucial role in the pathogenesis of NAFLD .Despite that there is currently no approved drug therapy for NAFLD, many approaches appear to be beneficial.Life style changes remains the cornerstone of treatment for NAFLD.Weight loss can improve hepatic steatosis,and 10% of weight loss may even improve fatty hepatitis.In addition,insulin sensitizers,antioxidants,lipid regulating and anti-inflammatory agents also show promising effects.The new preclinical tests show that the therapy based on incretin may improve the obesity,diabetes,and fatty degeneration of liver.Glucagan-Like peptide 1 analogues developed to treat diabe-tes show potential value in the treatment for NAFLD compared with the traditional treatment .At the same time,the continuous development of bariatric operation displays unique clinical significance in treating patients with NAFLD complicated by morbidly obese .

关 键 词：非酒精性脂肪肝 胰高糖素样肽1 减重手术 

分 类 号：R589.2[医药卫生—内分泌] R452[医药卫生—内科学]